Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition and Absolute Bioavailability of Muvalaplin in Healthy Males
NCT06342596Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of muvalaplin in elevated lipoprotein(a) (Lp(a)) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3473329 Radioactivity, Fecal Excretion of LY3473329 Radioactivity and 1 more. Started Mar 2024; status: completed.
02
Drugs
muvalaplin
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT06342596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342596.